ALUMIS INC.ALMSEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
ALUMIS INC. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for patients suffering from autoimmune and inflammatory disorders. It advances multiple product candidates through clinical trials, aiming to address unmet medical needs for patient populations across global markets.
ALMS Q2 FY2025 Key Financial Metrics
Revenue
$2.7M
Gross Profit
N/A
Operating Profit
$-140.5M
Net Profit
$59.3M
Gross Margin
N/A
Operating Margin
-5271.5%
Net Margin
2225.1%
YoY Growth
N/A
EPS
$0.77
ALUMIS INC. Q2 FY2025 Financial Summary
ALUMIS INC. reported revenue of $2.7M for Q2 FY2025, with a net profit of $59.3M (up 205.0% YoY) (2225.1% margin).
Key Financial Metrics
| Total Revenue | $2.7M |
|---|---|
| Net Profit | $59.3M |
| Gross Margin | N/A |
| Operating Margin | -5271.5% |
| Report Period | Q2 FY2025 |
ALUMIS INC. Quarterly Revenue & Net Profit History
ALUMIS INC. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $2.7M | — | $59.3M | 2225.1% |
| Q1 FY2025 | $17.4M | — | $-99.0M | -569.1% |
Income Statement
| Q1 2025 | Q2 2025 | |
|---|---|---|
| Revenue | $17.4M | $2.7M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | |
|---|---|---|
| Assets | $261.3M | $610.9M |
| Liabilities | $93.0M | $125.6M |
| Equity | $168.3M | $485.3M |
Cash Flow
| Q1 2025 | Q2 2025 | |
|---|---|---|
| Operating CF | $-80.4M | $-106.4M |